Pour plus de facilité, laissez cette case cochée. Sur les appareils partagés, nous vous conseillons de vous déconnecter d'Euroquity à la fin de votre utilisation
Email

Vous allez recevoir un email pour créer un nouveau mot de passe

Localisation

Choisissez votre pays

et votre langue

Bonjour ,

Bienvenue sur votre profil personnel. Votre carte de visite professionnelle présente votre activité principale. Elle sera visible sur EuroQuity.

% complété

%

medal 1
Ce profil est validé par 1 label.

Company

Immunitrack ApS

Immunitrack ApS_logo
23
EQ SCORE

L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.

Immunitrack’s mission is to provide the pharmaceutical industry and research community with technology and reagents to select or redesign drug candidates during early R&D and to monitor the effects of lead drug candidates on patient immune responses.

copenhagen, copenhagen, Denmark

Send a message

Anglais

Immunitrack ApS

Anglais

Immunitrrack is a biotech spinout from the university of Copenhagen. The company is currently developing a software solution for selection of cancer patients that are likely to repond to check-point blokade  treatments such as Ipilimumab or Novallumab.

There is currently a strong need for better diagnostic approaches in the selection of patients as only 1 in 5 cancer patients benefit from the treatment. This has consequences both to the non-responding patients...

See more

Immunitrrack is a biotech spinout from the university of Copenhagen. The company is currently developing a software solution for selection of cancer patients that are likely to repond to check-point blokade  treatments such as Ipilimumab or Novallumab.

There is currently a strong need for better diagnostic approaches in the selection of patients as only 1 in 5 cancer patients benefit from the treatment. This has consequences both to the non-responding patients that receive unnecessary toxic treatment but also to the heatlh care systems globabally as cost are expected to grow from 10,7Bn Euro in 2019 to 38.7 Bn Euro in 2023.

Our solution is a software, termed PrDx, with unmet accuracy in maping patient specific tumor neo-epitope load, as this is know to be a better biomarker to predict responders to check-point blockade treatment.

Immunitrack is founded upon world-leading research on MHC-epitope binding. Our proprietary epitope screening platform NeoScreen® measures the affinity and stability of MHC/epitope interactions, with capacity to rapidly screen libraries with thousands of (neo-)epitopes for applications within immuno-oncology, vaccine production, T cell therapies and immune monitoring.

The company is alreadycommercially active with over 170 clients and collaborators worldwide, providing reagents and data based on its NeoScreen Technology, for research and development of novel therapeutics.

 

  • 1

    Followers

  • 1

    Like

Team member(s)

Your request has been sent
Join this organization
Your request has been sent

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

InvestHorizon - Accelerated
The InvestHorizon Accelerated label is for selected deep tech companies from the accelerator programme to facilitate series A funding.  This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential. InvestHorizon is a programme financed by the European Commission in association with Eureka to foster investment readiness.
355 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
1920 Members